Fatalities from Tumor Lysis Syndrome (TLS) After Anti-Hyperuricemic Monotherapy - Nationally Representative, Propensity Score Matched, Retrospective Study Comparison of Rasburicase and Allopurinol

Authors

M S. Cairo, New York Medical College
J R. Gallagher
Y Barnes
E Drea
S Carrol

Author Type(s)

Faculty

Document Type

Abstract

Publication Date

10-2022

Journal Title

Clinical Lymphoma Myeloma & Leukemia

Department

Pediatrics

Recommended Citation

Cairo, M. S., Gallagher, J. R., Barnes, Y., Drea, E., & Carrol, S. (2022). Fatalities from Tumor Lysis Syndrome (TLS) After Anti-Hyperuricemic Monotherapy - Nationally Representative, Propensity Score Matched, Retrospective Study Comparison of Rasburicase and Allopurinol. Clinical Lymphoma Myeloma & Leukemia, 22, S302-S303. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/760